Increased plasma corticosterone levels after periaqueductal gray stimulation-induced escape reaction or panic attacks in rats

Behavioural Brain Research

Volumn 218, Issue 2, 2011, Pages 301-307

  Lim, Lee Wei ^a,b,c   Blokland, Arjan ^a,c   van Duinen, Marlies ^a,c   Visser Vandewalle, Veerle ^a,b   Tan, Sonny ^a,b,c   Vlamings, Rinske ^a,b,c   Janssen, Mark ^a,b,c   Jahanshahi, Ali ^a,b,c   Aziz Mohammadi, Mujzgan ^a,b,c   Steinbusch, Harry W M ^a,c   Schruers, Koen ^a,c   Temel, Yasin ^a,b,c  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c European Graduate School of Neuroscience   (Netherlands)

Author keywords

Corticosterone; Deep brain stimulation; Escape behaviour; Panic; Periaqueductal gray

Indexed keywords

BUSPIRONE; CORTICOSTERONE; ESCITALOPRAM; PROTEIN C FOS; SEROTONIN UPTAKE INHIBITOR;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; BRAIN DEPTH STIMULATION; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; ELECTRODE; ELECTROSTIMULATION; ESCAPE BEHAVIOR; HISTOPATHOLOGY; HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; NERVE CELL; NONHUMAN; OPEN FIELD TEST; PANIC; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; RAT;

ANALYSIS OF VARIANCE; ANIMALS; ANTI-ANXIETY AGENTS; BUSPIRONE; CITALOPRAM; CORTICOSTERONE; ELECTRIC STIMULATION; ESCAPE REACTION; FLUORESCENT ANTIBODY TECHNIQUE; MALE; NEURONS; PANIC; PERIAQUEDUCTAL GRAY; PROTO-ONCOGENE PROTEINS C-FOS; RADIOIMMUNOASSAY; RATS; RATS, WISTAR; SEROTONIN UPTAKE INHIBITORS;

EID: 79151479003     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2010.12.026     Document Type: Article

References (74)

1. Abelson J.L., Nesse R.M., Vinik A.I. Pentagastrin infusions in patients with panic disorder II. Neuroendocrinol. Biol Psychiatry 1994, 36:84-96.
2. Amano K., Tanikawa T., Iseki H., Kawabatake H., Notani M., Kawamura H., et al. Single neuron analysis of the human midbrain tegmentum. Rostral mecencephalic reticulotomy for pain relief. Appl Neurophysiol 1978, 41:66-78.
3. Argyropoulos S.V., Bailey J.E., Hood S.D., Kendrick A.H., Rich A.S., Laszlo G., et al. Inhalation of 35% CO(2) results in activation of the HPA axis in healthy volunteers. Psychoneuroendocrinology 2002, 27:715-729.
4. Bandelow B., Wedekind D., Pauls J., Broocks A., Hajak G., Ruther E. Salivary cortisol in panic attacks. Am J Psychiatry 2000, 157:454-456.
5. Benjamin J., Nemetz H., Fux M., Bleichman I., Agam G. Acute inositol does not attenuate m-CPP-induced anxiety, mydriasis and endocrine effects in panic disorder. J Psychiatr Res 1997, 31:489-495.
6. Berrino L., Pizzirusso A., Maione S., Vitagliano S., D'Amico M., Rossi F. Hypothalamic paraventricular nucleus involvement in the pressor response to N-methyl-d-aspartic acid in the periaqueductal grey matter. Naunyn Schmiedebergs Arch Pharmacol 1996, 353:157-160.
7. Broocks A., Bandelow B., George A., Jestrabeck C., Opitz M., Bartmann U., et al. Increased psychological responses and divergent neuroendocrine responses to m-CPP and ipsapirone in patients with panic disorder. Int Clin Psychopharmacol 2000, 15:153-161.
8. Cameron O.G., Lee M.A., Curtis G.C., McCann D.S. Endocrine and physiological changes during "spontaneous" panic attacks. Psychoneuroendocrinology 1987, 12:321-331.
9. Charney D.S., Woods S.W., Goodman W.K., Heninger G.R. Serotonin function in anxiety II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects. Psychopharmacology (Berl.) 1987, 92:14-24.
10. Crine A.F., Louis F., Sulon J., Legros J.J. Changes in total serum immunoreactive neurophysins and corticosterone levels after restraint stress in rats. Psychoneuroendocrinology 1983, 8:447-450.
11. Davidson R.J. Anxiety, depression, and emotion: anxiety, depression Sas C 2000, Oxford University Press, 77-78.
12. de Kloet E.R., Joels M., Holsboer F. Stress and the brain: from adaptation to disease. Nat Rev Neurosci 2005, 6:463-475.
13. Dinan T.G. Serotonin and the regulation of hypothalamic-pituitary-adrenal axis function. Life Sci 1996, 58:1683-1694.
14. Engelmann M., Landgraf R., Wotjak C.T. The hypothalamic-neurohypophysial system regulates the hypothalamic-pituitary-adrenal axis under stress: an old concept revisited. Front Neuroendocrinol 2004, 25:132-149.
15. Fuller R.W. Serotonin receptors involved in regulation of pituitary-adrenocortical function in rats. Behav Brain Res 1996, 73:215-219.
16. Graeff F.G., Garcia-Leal C., Del-Ben C.M., Guimaraes F.S. Does the panic attack activate the hypothalamic-pituitary-adrenal axis?. An Acad Bras Cienc 2005, 77:477-491.
17. Griez E., Schruers K. Experimental pathophysiology of panic. J Psychosom Res 1998, 45:493-503.
18. Gurguis G.N., Vitton B.J., Uhde T.W. Behavioral, sympathetic and adrenocortical responses to yohimbine in panic disorder patients and normal controls. Psychiatry Res 1997, 71:27-39.
19. Hjorth S., Bengtsson H.J., Kullberg A., Carlzon D., Peilot H., Auerbach S.B. Serotonin autoreceptor function and antidepressant drug action. J Psychopharmacol 2000, 14:177-185.
20. Hogg S., Michan L., Jessa M. Prediction of anti-panic properties of escitalopram in the dorsal periaqueductal grey model of panic anxiety. Neuropharmacology 2006, 51:141-145.
21. Hollander E., Liebowitz M.R., Gorman J.M., Cohen B., Fyer A., Klein D.F. Cortisol and sodium lactate-induced panic. Arch Gen Psychiatry 1989, 46:135-140.
22. Hood S.D., Hince D.A., Robinson H., Cirillo M., Christmas D., Kaye J.M. Serotonin regulation of the human stress response. Psychoneuroendocrinology 2006, 31:1087-1097.
23. Jenck F., Moreau J.L., Martin J.R. Dorsal periaqueductal gray-induced aversion as a simulation of panic anxiety: elements of face and predictive validity. Psychiatry Res 1995, 57:181-191.
24. Judd F.K., Apostolopoulos M., Burrows G.D., Norman T.R. Serotonergic function in panic disorder: endocrine responses to D-fenfluramine. Prog Neuropsychopharmacol Biol Psychiatry 1994, 18:329-337.
25. Kahn R.S., Asnis G.M., Wetzler S., van Praag H.M. Neuroendocrine evidence for serotonin receptor hypersensitivity in panic disorder. Psychopharmacology (Berl.) 1988, 96:360-364.
26. Kakui N., Yokoyama F., Yamauchi M., Kitamura K., Imanishi T., Inoue T., et al. Anxiolytic-like profile of mirtazapine in rat conditioned fear stress model: Functional significance of 5-hydroxytryptamine 1A receptor and alpha1-adrenergic receptor. Pharmacol Biochem Behav 2009, 92:393-398.
27. Kaye J., Buchanan F., Kendrick A., Johnson P., Lowry C., Bailey J., et al. Acute carbon dioxide exposure in healthy adults: evaluation of a novel means of investigating the stress response. J Neuroendocrinol 2004, 16:256-264.
28. Khan S., Liberzon I., Abelson J.L. Effects of propranolol on symptom and endocrine responses to pentagastrin. Psychoneuroendocrinology 2004, 29:1163-1171.
29. Klein E., Zohar J., Geraci M.F., Murphy D.L., Uhde T.W. Anxiogenic effects of m-CPP in patients with panic disorder: comparison to caffeine's anxiogenic effects. Biol Psychiatry 1991, 30:973-984.
30. Liebowitz M.R., Gorman J.M., Fyer A.J., Levitt M., Dillon D., Levy G., et al. Lactate provocation of panic attacks II. Biochemical and physiological findings. Arch Gen Psychiatry 1985, 42:709-719.
31. Lim L.W., Blokland A., Tan S., Vlamings R., Sesia T., Aziz-Mohammadi M., et al. Attenuation of fear-like response by escitalopram treatment after electrical stimulation of the midbrain dorsolateral periaqueductal gray. Exp Neurol 2010, 226:293-300.
32. Lim L.W., Blokland A., Visser-Vandewalle V., Vlamings R., Sesia T., Steinbusch H., et al. High-frequency stimulation of the dorsolateral periaqueductal gray and ventromedial hypothalamus fails to inhibit panic-like behaviour. Behav Brain Res 2008, 193:197-203.
33. Lim L.W., Temel Y., Sesia T., Vlamings R., Visser-Vandewalle V., Steinbusch H.W., et al. Buspirone induced acute and chronic changes of neural activation in the periaqueductal gray of rats. Neuroscience 2008, 155:164-173.
34. Lim L.W., Temel Y., Visser-Vandewalle V., Blokland A., Steinbusch H. Fos immunoreactivity in the rat forebrain induced by electrical stimulation of the dorsolateral periaqueductal gray matter. J Chem Neuroanat 2009, 38:83-96.
35. Lim L.W., Temel Y., Visser-Vandewalle V., Steinbusch H., Schruers K., Hameleers R., et al. Effect of buspirone on the behavioral regulation of rats in low versus high anxiety conditions. Arzneimittelforschung 2008, 58:269-276.
36. Lin A.S., Uhde T.W., Slate S.O., McCann U.D. Effects of intravenous caffeine administered to healthy males during sleep. Depress Anxiety 1997, 5:21-28.
37. Lorens S.A., Van de Kar L.D. Differential effects of serotonin (5-HT1A and 5-HT2) agonists and antagonists on renin and corticosterone secretion. Neuroendocrinology 1987, 45:305-310.
38. Lugenbiel P., Sartorius A., Vollmayr B., Schloss P. Creatine transporter expression after antidepressant therapy in rats bred for learned helplessness. World J Biol Psychiatry 2009, 1-5.
39. Matheson G.K., Gage D., White G., Dixon V., Gipson D. A comparison of the effects of buspirone and diazepam on plasma corticosterone levels in rat. Neuropharmacology 1988, 27:823-830.
40. McAllister-Williams R.H., Anderson A.J., Young A.H. Corticosterone selectively attenuates 8-OH-DPAT-mediated hypothermia in mice. Int J Neuropsychopharmacol 2001, 4:1-8.
41. McCann U.D., Slate S.O., Geraci M., Roscow-Terrill D., Uhde T.W. A comparison of the effects of intravenous pentagastrin on patients with social phobia, panic disorder and healthy controls. Neuropsychopharmacology 1997, 16:229-237.
42. McNally R.J., Lukach B.M. Are panic attacks traumatic stressors?. Am J Psychiatry 1992, 149:824-826.
43. Nashold B.S., Wilson W.P., Slaughter D.G. Sensations evoked by stimulation in the midbrain of man. J Neurosurg 1969, 30:14-24.
44. Ninan P. Buspirone and gepirone. Textbook of psychopharmcology 2004, 391-404. American Psychiatric Publishing, Washington, DC. 3rd ed. A.F. Schatzberg, C.B. Nemeroff (Eds.).
45. Nutt D.J., Ballenger J.C. Anxiety disorders 2003, Blackwell Publishing, 280-1.
46. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1998, Academic Press. 4th ed.
47. Peskind E.R., Jensen C.F., Pascualy M., Tsuang D., Cowley D., Martin D.C., et al. Sodium lactate and hypertonic sodium chloride induce equivalent panic incidence, panic symptoms, and hypernatremia in panic disorder. Biol Psychiatry 1998, 44:1007-1016.
48. Pineyro G., Blier P. Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacol Rev 1999, 51:533-591.
49. Pittman Q.J., Blume H.W., Renaud L.P. Connections of the hypothalamic paraventricular nucleus with the neurohypophysis, median eminence, amygdala, lateral septum and midbrain periaqueductal gray: an electrophysiological study in the rat. Brain Res 1981, 215:15-28.
50. Roy-Byrne P.P., Craske M.G., Stein M.B. Panic disorder. Lancet 2006, 368:1023-1032.
51. Sanchez C., Bergqvist P.B., Brennum L.T., Gupta S., Hogg S., Larsen A., et al. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology (Berl.) 2003, 167:353-362.
52. Sasaki I., Akiyoshi J., Sakurai R., Tsutsumi T., Ono H., Yamada K., et al. Carbon dioxide induced panic attack in panic disorder in Japan. Prog Neuropsychopharmacol Biol Psychiatry 1996, 20:1145-1157.
53. Schenberg L.C., Dos Reis A.M., Ferreira Povoa R.M., Tufik S., Silva S.R. A panic attack-like unusual stress reaction. Horm Behav 2008, 54:584-591.
54. Schreiber W., Lauer C.J., Krumrey K., Holsboer F., Krieg J.C. Dysregulation of the hypothalamic-pituitary-adrenocortical system in panic disorder. Neuropsychopharmacology 1996, 15:7-15.
55. Sinha S.S., Coplan J.D., Pine D.S., Martinez J.A., Klein D.F., Gorman J.M. Panic induced by carbon dioxide inhalation and lack of hypothalamic-pituitary-adrenal axis activation. Psychiatry Res 1999, 86:93-98.
56. Strohle A., Holsboer F., Rupprecht R. Increased ACTH concentrations associated with cholecystokinin tetrapeptide-induced panic attacks in patients with panic disorder. Neuropsychopharmacology 2000, 22:251-256.
57. Sulon J., Demey-Ponsart L., Beauduin P., Sodoyez J.C. Radioimmunoassay of corticosterone, cortisol and cortisone: their application to human cord and maternal plasma. J Steroid Biochem 1978, 9:671-676.
58. Takao K., Nagatani T., Kitamura Y., Yamawaki S. Effects of corticosterone on 5-HT1A and 5-HT2 receptor binding and on the receptor-mediated behavioral responses of rats. Eur J Pharmacol 1997, 333:123-128.
59. Targum S.D. Differential responses to anxiogenic challenge studies in patients with major depressive disorder and panic disorder. Biol Psychiatry 1990, 28:21-34.
60. Targum S.D., Marshall L.E. Fenfluramine provocation of anxiety in patients with panic disorder. Psychiatry Res 1989, 28:295-306.
61. Temel Y., Visser-Vandewalle V., van der Wolf M., Spincemaille G.H., Desbonnet L., Hoogland G., et al. Monopolar versus bipolar high frequency stimulation in the rat subthalamic nucleus: differences in histological damage. Neurosci Lett 2004, 367:92-96.
62. Tsuji M., Takeda H., Matsumiya T. Protective effects of 5-HT1A receptor agonists against emotional changes produced by stress stimuli are related to their neuroendocrine effects. Br J Pharmacol 2001, 134:585-595.
63. Tunnicliff G., Brokaw J.J., Hausz J.A., Matheson G.K., White G.W. Influence of repeated treatment with buspirone on central 5-hydroxytryptamine and dopamine synthesis. Neuropharmacology 1992, 31:991-995.
64. van Duinen M.A., Schruers K.R., Maes M., Griez E.J. CO2 challenge results in hypothalamic-pituitary-adrenal activation in healthy volunteers. J Psychopharmacol 2005, 19:243-247.
65. van Duinen M.A., Schruers K.R., Maes M., Griez E.J. CO2 challenge induced HPA axis activation in panic. Int J Neuropsychopharmacol 2007, 10:797-804.
66. van Megen H.J., Westenberg H.G., den Boer J.A., Haigh J.R., Traub M. Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients. Psychopharmacology (Berl.) 1994, 114:449-455.
67. van Megen H.J., Westenberg H.G., Den Boer J.A., Kahn R.S. The panic-inducing properties of the cholecystokinin tetrapeptide CCK4 in patients with panic disorder. Eur Neuropsychopharmacol 1996, 6:187-194.
68. Wiegert O., Joels M., Krugers H. Timing is essential for rapid effects of corticosterone on synaptic potentiation in the mouse hippocampus. Learn Mem 2006, 13:110-113.
69. Woods S.W., Charney D.S., Goodman W.K., Heninger G.R. Carbon dioxide-induced anxiety. Behavioral, physiologic, and biochemical effects of carbon dioxide in patients with panic disorders and healthy subjects. Arch Gen Psychiatry 1988, 45:43-52.
70. Woods S.W., Charney D.S., McPherson C.A., Gradman A.H., Heninger G.R. Situational panic attacks. Behavioral, physiologic, and biochemical characterization. Arch Gen Psychiatry 1987, 44:365-375.
71. Young A.H., Goodwin G.M., Dick H., Fink G. Effects of glucocorticoids on 5-HT1A presynaptic function in the mouse. Psychopharmacology (Berl.) 1994, 114:360-364.
72. Zangenehpour S., Chaudhuri A. Differential induction and decay curves of c-fos and zif268 revealed through dual activity maps. Brain Res Mol Brain Res 2002, 109:221-225.
73. Zwanzger P., Baghai T.C., Schuele C., Strohle A., Padberg F., Kathmann N., et al. Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4) induced panic in healthy volunteers. Neuropsychopharmacology 2001, 25:699-703.
74. Zwanzger P., Eser D., Aicher S., Schule C., Baghai T.C., Padberg F., et al. Effects of alprazolam on cholecystokinin-tetrapeptide-induced panic and hypothalamic-pituitary-adrenal-axis activity: a placebo-controlled study. Neuropsychopharmacology 2003, 28:979-984.